NCT06176079View on ClinicalTrials.gov

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Fatty LiverNon Alcoholic SteatohepatitisNAFLDNASH
Interventions
DRUG

Hyperpolarized (HP) 13C

A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

DRUG

Hyperpolarized 13C-Urea

Given intravenously (IV)

PROCEDURE

Magnetic Resonance Imaging

Imaging procedure

PROCEDURE

Saline Flush

A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Michael Ohliger, MD PhD

OTHER